Mark F Lew

Summary

Affiliation: University of Southern California
Country: USA

Publications

  1. ncbi Safety and efficacy of newly formulated selegiline orally disintegrating tablets as an adjunct to levodopa in the management of 'off' episodes in patients with Parkinson's disease
    Mark F Lew
    Keck University of Southern California School of Medicine, Los Angeles, CA 90033, USA
    Curr Med Res Opin 23:741-50. 2007
  2. doi Immediate versus delayed switch from levodopa/carbidopa to levodopa/carbidopa/entacapone: effects on motor function and quality of life in patients with Parkinson's disease with end-of-dose wearing off
    Mark F Lew
    Department of Neurology, Division of Movement Disorders, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    Int J Neurosci 121:605-13. 2011
  3. ncbi Results from a 2-year centralized tolcapone liver enzyme monitoring program
    Mark F Lew
    Keck University of Southern California School of Medicine, 1520 San Pablo Street, Los Angeles, CA 90033, USA
    Clin Neuropharmacol 30:281-6. 2007
  4. doi The evidence for disease modification in Parkinson's disease
    Mark F Lew
    Department of Neurology, Keck USC School of Medicine, Los Angeles, California 90033, USA
    Int J Neurosci 121:18-26. 2011
  5. ncbi Selegiline orally disintegrating tablets for the treatment of Parkinson's disease
    Mark F Lew
    Department of Neurology, University of Southern California, Keck School of Medicine, 1520 San Pablo St, HCC 2, Ste, 3000, Los Angeles, CA 90033, USA
    Expert Rev Neurother 5:705-12. 2005
  6. pmc The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study
    Jeanne C Latourelle
    Department of Neurology, Boston University School of Medicine, Boston University, Boston, MA, USA
    BMC Med 6:32. 2008
  7. ncbi Long-term efficacy of rasagiline in early Parkinson's disease
    Mark F Lew
    Department of Neurology, Keck University of Southern California School of Medicine, Los Angeles, California 90033, USA
    Int J Neurosci 120:404-8. 2010
  8. pmc Impact of belief in neuroprotection on therapeutic intervention in Parkinson's disease
    Rodger J Elble
    Department of Neurology, Southern Illinois University School of Medicine, Springfield, Illinois, USA
    Mov Disord 25:1082-6. 2010
  9. ncbi Review of the FDA-approved uses of botulinum toxins, including data suggesting efficacy in pain reduction
    Mark F Lew
    Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
    Clin J Pain 18:S142-6. 2002
  10. ncbi Rasagiline treatment effects on parkinsonian tremor
    Mark F Lew
    Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
    Int J Neurosci 123:859-65. 2013

Detail Information

Publications20

  1. ncbi Safety and efficacy of newly formulated selegiline orally disintegrating tablets as an adjunct to levodopa in the management of 'off' episodes in patients with Parkinson's disease
    Mark F Lew
    Keck University of Southern California School of Medicine, Los Angeles, CA 90033, USA
    Curr Med Res Opin 23:741-50. 2007
    ..This study assessed adjunctive Zelapar (selegiline orally disintegrating tablet (ODT)) for managing off episodes and for long-term safety...
  2. doi Immediate versus delayed switch from levodopa/carbidopa to levodopa/carbidopa/entacapone: effects on motor function and quality of life in patients with Parkinson's disease with end-of-dose wearing off
    Mark F Lew
    Department of Neurology, Division of Movement Disorders, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    Int J Neurosci 121:605-13. 2011
    ..Assess motor function and quality of life (QoL) in Parkinson's disease (PD) subjects with end-of-dose wearing off (EODWO), comparing immediate and delayed switch (IS, DEL) to levodopa/carbidopa/entacapone (LCE)...
  3. ncbi Results from a 2-year centralized tolcapone liver enzyme monitoring program
    Mark F Lew
    Keck University of Southern California School of Medicine, 1520 San Pablo Street, Los Angeles, CA 90033, USA
    Clin Neuropharmacol 30:281-6. 2007
    ....
  4. doi The evidence for disease modification in Parkinson's disease
    Mark F Lew
    Department of Neurology, Keck USC School of Medicine, Los Angeles, California 90033, USA
    Int J Neurosci 121:18-26. 2011
    ..This review will discuss in detail the design and results of clinical trials for varied medical therapies that were specifically undertaken to discern whether a particular treatment might be disease modifying in the treatment of PD...
  5. ncbi Selegiline orally disintegrating tablets for the treatment of Parkinson's disease
    Mark F Lew
    Department of Neurology, University of Southern California, Keck School of Medicine, 1520 San Pablo St, HCC 2, Ste, 3000, Los Angeles, CA 90033, USA
    Expert Rev Neurother 5:705-12. 2005
    ..Selegiline orally disintegrating tablet has been demonstrated to be safe and well tolerated in placebo-controlled clinical trials...
  6. pmc The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study
    Jeanne C Latourelle
    Department of Neurology, Boston University School of Medicine, Boston University, Boston, MA, USA
    BMC Med 6:32. 2008
    ..Studies of the penetrance of LRRK2 mutations have produced a wide range of estimates, possibly due to differences in study design and recruitment, including in particular differences between samples of familial PD versus sporadic PD...
  7. ncbi Long-term efficacy of rasagiline in early Parkinson's disease
    Mark F Lew
    Department of Neurology, Keck University of Southern California School of Medicine, Los Angeles, California 90033, USA
    Int J Neurosci 120:404-8. 2010
    ..Rasagiline was well tolerated, with 11.3% of patients (45/398) withdrawing because of an adverse event. Rasagiline therapy for PD was effective, well tolerated, and safe in this long-term trial...
  8. pmc Impact of belief in neuroprotection on therapeutic intervention in Parkinson's disease
    Rodger J Elble
    Department of Neurology, Southern Illinois University School of Medicine, Springfield, Illinois, USA
    Mov Disord 25:1082-6. 2010
    ..We found the investigators' level of confidence in these agents had no effect on the time to symptomatic therapy or on the change in UPDRS during 12 months of treatment...
  9. ncbi Review of the FDA-approved uses of botulinum toxins, including data suggesting efficacy in pain reduction
    Mark F Lew
    Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
    Clin J Pain 18:S142-6. 2002
    ..Studies conducted in patients with cervical dystonia have shown that botulinum toxin effectively reduces pain associated with this disorder, suggesting that this agent may be effective in alleviating other painful syndromes...
  10. ncbi Rasagiline treatment effects on parkinsonian tremor
    Mark F Lew
    Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
    Int J Neurosci 123:859-65. 2013
    ..These data suggest that rasagiline used as monotherapy and as adjunctive therapy is effective for reducing tremor severity in patients with PD...
  11. ncbi Duration of effectiveness of botulinum toxin type B in the treatment of cervical dystonia
    Mark F Lew
    Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
    Adv Neurol 94:211-5. 2004
  12. ncbi Behavioral changes as side effects of medication treatment for Parkinson's disease
    Jennifer S Hui
    Department of Neurology, Keck University of Southern California School of Medicine, Los Angeles, California, USA
    Adv Neurol 96:114-29. 2005
  13. doi RimabotulinumtoxinB effects on pain associated with cervical dystonia: results of placebo and comparator-controlled studies
    Mark F Lew
    Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA
    Int J Neurosci 120:298-300. 2010
    ..6 vs. 1.8; p = .1651). These results support the consideration of BoNT-B as an effective first-line botulinum toxin treatment for patients with CD who list pain as a primary complaint...
  14. pmc Huntington CAG repeat size does not modify onset age in familial Parkinson's disease: the GenePD study
    Christopher F McNicoll
    Department of Neurology, Boston University School of Medicine, Boston University, Boston, Massachusetts 02118, USA
    Mov Disord 23:1596-601. 2008
    ..No relation between the HD CAG repeat size and the age at onset for PD was found in this sample of familial PD...
  15. pmc PARK3 influences age at onset in Parkinson disease: a genome scan in the GenePD study
    Anita L Destefano
    Department of Neurology, Boston University Schools of Medicine and of Public Health, Boston, MA 02118, USA
    Am J Hum Genet 70:1089-95. 2002
    ....
  16. ncbi Transtelephonic home blood pressure to assess the monoamine oxidase-B inhibitor rasagiline in Parkinson disease
    William B White
    Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center and Clinical Trials Unit, University of Connecticut, Farmington, Connecticut 06030 3940, USA
    Hypertension 52:587-93. 2008
    ..3%, 2.6%, and 2.9% of the placebo, 0.5-mg, and 1.0-mg rasagiline groups, respectively. These data demonstrate that rasagiline did not induce postprandial hypertension in patients with Parkinson disease who were on an unrestricted diet...
  17. ncbi Influence of heterozygosity for parkin mutation on onset age in familial Parkinson disease: the GenePD study
    Mei Sun
    Molecular Neurogenetics Unit, Center for Human Genetic Research, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA
    Arch Neurol 63:826-32. 2006
    ..The PARK2 gene at 6q26 encodes parkin, whose inactivation is implicated in an early-onset autosomal recessive form of Parkinson disease (PD)...
  18. ncbi Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study
    Daniel Truong
    The Parkinson s and Movement Disorders Institute, Fountain Valley, California 92708, USA
    Mov Disord 20:783-91. 2005
    ..These results confirm previous reports that Dysport (500 units) is safe, effective, and well-tolerated in patients with cervical dystonia...
  19. pmc Replication of association between ELAVL4 and Parkinson disease: the GenePD study
    Anita L Destefano
    Department of Biostatistics, Boston University School of Public Health, 715 Albany Street, Crosstown Center, 3rd Floor, Boston, MA 02118, USA
    Hum Genet 124:95-9. 2008
    ..This replication of association with rs967582 in a third cohort further implicates ELAVL4 as a PD susceptibility gene...